Cadrenal Therapeutics CFO Matthew Szot separated from company effective May 28, 2026
Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, separated from the company on May 28, 2026, with a severance package of $365,806 payable in installments through September 2026. The departure represents a leadership change at the biopharmaceutical company during a period of operational restructuring.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day